This study evaluates the clinical activity of daratumumab, an anti-PD-L1 monoclonal antibody in metastatic NSCLC with LKB1 mutation who have received previous standard treatment. An overall response rate ≥20% is considered clinically meaningful. The gene discussed is CD274; the disease is non-small cell lung carcinoma.